Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
In Reply: We agree with Dr Dunavant that no
single clinical trial should be considered in isolation. We point out that
another study1 has found that nesiritide
is safe and effective in improving hemodynamics, specifically PCWP and pulmonary
artery pressures in patients with decompensated CHF. Our trial, as well as
the earlier report by Colucci et al,1 demonstrated
that nesiritide led to rapid reduction in PCWP, which is directly related
to improvement of CHF symptoms. Indeed, in our trial, nesiritide consistently
was associated with a greater decrease in PCWP during the first 24 hours than
nitroglycerin at all time points except at 2 hours.
Young JB. Nesiritide vs Nitroglycerin for Decompensated Congestive Heart Failure—Reply. JAMA. 2002;288(5):571–573. doi:10.1001/jama.288.5.571
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: